PennantPark Investment (PNNT) Stock Rating Upgraded by Zacks Investment Research

Elias Hubbard
May 4, 2018

Eventide Asset Management Llc acquired 25,600 shares as Sage Therapeutics Inc (SAGE)'s stock declined 6.84%. Dean Capital Investments Management LLC acquired a new stake in shares of PennantPark Investment during the fourth quarter worth $193,000. Sage Therapeutics Inc now has $6.85 billion valuation. The Manufacturers Life Insurance Company now owns 28,044 shares of the asset manager's stock valued at $207,000 after purchasing an additional 23,747 shares during the period.

Several other large investors have also recently modified their holdings of PNNT. It has outperformed by 124.40% the S&P500. Mckinley Capital Management Inc sold 87,882 shares as Pennantpark Invt Corp (PNNT)'s stock declined 3.30%. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data. Pennantpark Invt Corp now has $474.69M valuation. Ticker's shares touched $6.67 during the last trading session after 0.52% change.Currently PennantPark Investment Corporation is downtrending after 13.46% change in last May 4, 2017. About 15,780 shares traded. It has underperformed by 25.01% the S&P500.

During Q4 2017 the big money sentiment increased to 1.18. The latest exchange of 0.05 Million shares is below its average trading activity of 36.94 Million shares. The ratio increased due to PennantPark Investment Corporation positioning: 12 sold and 28 reduced.

Zacks Investment Research upgraded shares of PennantPark Investment (NASDAQ:PNNT) from a hold rating to a buy rating in a report published on Wednesday, April 11th. Deutsche Financial Bank Ag holds 14,917 shares or 0% of its portfolio. Millennium Mgmt Ltd Liability invested in 440,329 shares. Stifel Corporation reported 33,220 shares or 0% of all its holdings. Eqis Capital Management Inc. acquired a new stake in shares of PennantPark Investment during the fourth quarter worth $143,000. Clearbridge Ltd Liability Corporation owns 1.20 million shs.

On May, 14 is awaited PennantPark Investment Corporation (NASDAQ:PNNT)'s earnings report, RTT reports. Carroll Financial has 2,600 shares. PennantPark Investment Corporation is managed by PennantPark Investment Advisers, LLC. Koch Incorporated holds 0.03% in PennantPark Investment Corporation (NASDAQ:PNNT) or 26,684 shs.

Goldman Sachs Group reported 159,459 shs or 0% of all its holdings. 90,740 are owned by Aperio Gp Ltd Liability Company. Barclays Public Ltd Co reported 94 shares. Therefore 42% are positive. Pennant Investment had 34 analyst reports since August 6, 2015 according to SRatingsIntel. Finally, Ladenburg Thalmann raised PennantPark Investment from a "neutral" rating to a "buy" rating and set a $8.00 target price for the company in a research note on Friday, February 9th. On Friday, January 19 the stock of PennantPark Investment Corporation (NASDAQ:PNNT) has "Hold" rating given by Jefferies. As per Monday, July 24, the company rating was maintained by Keefe Bruyette & Woods. ValuEngine downgraded PennantPark Investment from a "buy" rating to a "hold" rating in a report on Wednesday. The stock has "Neutral" rating by JP Morgan on Monday, July 18. J.P. Morgan has "Buy" rating and $8.5000 target. Zacks Investment Research raised PennantPark Investment from a "strong sell" rating to a "hold" rating in a research note on Saturday, February 3rd. The stock now has a consensus rating of "Hold" and a consensus target price of $8.30. As per Friday, October 27, the company rating was maintained by RBC Capital Markets. Jefferies maintained the shares of SC in report on Monday, October 16 with "Buy" rating. Analysts forecast $0.18 earnings per share. PennantPark Investment's revenue was down 10.0% compared to the same quarter previous year. It also upped Prospect Capital Corporation (NASDAQ:PSEC) stake by 136,232 shares and now owns 765,052 shares. Analysts predict $0.18 EPS, which is $0.05 down or 21.74 % from 2017's $0.23 EPS. $9.57 million worth of Sage Therapeutics, Inc. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Therefore 89% are positive. 0 analysts call it Underweight, while 3 think it is Overweight. (NYSE:SC) earned "Buy" rating by Compass Point on Thursday, April 27. The rating was maintained by Leerink Swann with "Buy" on Tuesday, September 12. On Wednesday, November 23 the stock rating was downgraded by FBR Capital to "Mkt Perform". The stock of Sage Therapeutics, Inc. The rating was maintained by BMO Capital Markets with "Buy" on Wednesday, January 31.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER